← SynDRA
DACARBAZINE
SynDRA canonical compound SYN0000373 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PGD | POLA2 |
|---|
| Mechanism of action | DNA alkylating agent |
|---|
| Indication | Hodgkin's lymphoma | melanoma |
|---|
| Disease area | hematologic malignancy | oncology |
|---|
All known targets
Mechanisms of action (all sources)
Drug classes
- Alkylating Activity
- Alkylating Drug
- Alkylating Agents
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Noxae
ATC classes
Cross-references
Synonyms
- deticene
- Dacarbazina
- Biocarbazine r
- Dacarbasine
- Dacarbazinum
- Decarbazine
- Dicarbazine
- DIC
- DTIC
- NCI C04717
- NSC-45388
- Dtic-dome
- Biocarbazin
- Biocarbazine
- DTICDome
- DTIE
- Dacarbazino
- Dacatic
- Deticene
- Dimethyltriazenoimidazolecarboxamide
- ICDMT
- ICDT
- Biocarbazine R
- DTIC-Dome
- Dimethyl Imidazole Carboxamide
- Dimethyl Triazeno Imidazole Carboxamide
- Imidazole carboxamide
- HE1150000
- Carboxamide (TN)
- Carboxamide, Dimethyl Imidazole
- DIC (TN)
- DTIC (TN)
- Dacarbazino [INN-Spanish]
- Dacarbazinum [INN-Latin]
- Imidazole (TN)
- Imidazole Carboxamide, Dimethyl
- NPFAPI-05
- DTIC-Dome (TN)
Reported adverse events
- Hepatic necrosis
- Alopecia
Look up DACARBAZINE in the interactive SynDRA portal →